Study of RPL8 protein in ovarian cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This study looks at a protein called RPL8 in a specific type of ovarian cancer called high-grade serous ovarian carcinoma. It may help researchers understand the disease better and find new ways to treat it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with high-grade (grade 3 or 4) serous ovarian cancer, either when first found or when it has come back.
- You have signed a consent form agreeing to take part in the study.
- Your ovarian tumor is not a different type (like clear cell or endometrioid).
- You do not have another type of cancer (other than ovarian).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special imaging technique to study high-grade serous ovarian cancer. It aims to better understand the tumor to improve treatment. If you have advanced ovarian cancer and are scheduled for surgery, you may be eligible.
This study is for people with a specific type of ovarian cancer (high-grade serous) who have not yet had surgery. It looks at how the cancer may resist standard chemotherapy and aims to find ways to overcome that resistance.
This study looks at how medical images relate to genetic patterns in high-grade serous ovarian cancer. It may help find better ways to diagnose and treat this specific type of ovarian cancer.
This study looks at genetic changes in ovarian cancer to find possible targeted treatments. It may help you if you have certain types of ovarian cancer and are seeking more personalized care.
This study examines tissue samples from women with a specific type of ovarian cancer (high-grade serous) to measure how much of a protein called folate receptor alpha is present. Understanding this protein level may help doctors identify which patients could benefit from targeted treatments in the future.
This study looks at a marker called folate receptor alpha in tissue samples from people with ovarian, fallopian tube, or primary peritoneal cancer that has returned. The goal is to see how common this marker is, which may help guide future treatment options.
Hear when a new High Grade Serous Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.